All potential acute ischemic stroke patients meeting criteria for the use of IV tPA should be offered treatment. The facts are clear, and all that remains is further provider and patient education.

For patients with ischemic stroke, tenecteplase seems to be a reasonable alternative to alteplase in terms of effecti ...

A clot-dissolving tissue plasminogen activator (tPA), tenecteplase is now indicated for acute ischemic stroke on top of its older approval in acute ST-elevation myocardial infarction. Tenecteplase ...

IV tPA remains the standard of care of acute ischemic stroke patients presenting within established time windows without contraindications, and hospitals should continue to concentrate on system ...

The usage of tenecteplase in patients with acute ischemic stroke was associated with similar effectiveness and safety ...

Intravenous delivered tPA is approved by the FDA for the treatment of acute ischemic stroke. The drug can make a big difference, but only if it is given within a specified time frame (up to four and a ...

A brain stroke occurs when blood flow to the brain is disrupted, leading to severe damage. Recognizing symptoms early and ...

March 4, 2025 -- The FDA has approved the first new clot-busting drug in nearly 30 years, offering a faster way to dissolve blood clots in adults who suffer a stroke. The treatment ...

In the US, the rate of ischemic stroke among adults aged 20 to 44 surged from 17 per 100,000 adults in 1993 to 28 per 100,000 in 2015. The risk of stroke death among young adults is also on the rise.